Lundbeck and Takeda announce Ministry of Health, Labour and Welfare (MHLW) approval of Trintellix ® in Japan
• New treatment option with a new pharmacological profile for adult patients with Major Depressive Disorder (MDD) and depressed state in Japan • Phase III clinical trial in Japan with 493 adults with major depressive disorder show that the vortioxetine groups demonstrated statistically significant antidepressant efficacy compared to the placebo group • There are approximately three million patients with the disease in Japan, affecting 2.5% of the population*H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)